We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug & Device Products
FDAnews Books Library
Events
Form 483s Database
Publications
Webinar Training Pass
eCFR and Guidances
Books
Clinical Products
Advertising
White Papers
Contact Us
About Us
COVID-19
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Michele L. Glendenning
Michele L. Glendenning
Products
PRODUCTS
Amsino Healthcare (USA), Inc.
Michele L. Glendenning
and
Jesse A. Vazquez
Price:
$117.00
View
Hydrox Laboratories
Michele L. Glendenning
and
Kevin P. Regan
Price:
$117.00
View
Fresenius Kabi USA, LLC
Michele L. Glendenning
and
Brian D. Nicholson
Price:
$117.00
View
Surmasis Pharmaceutical
Michele L. Glendenning
and
Peng Zhou
Price:
$117.00
View
Brenntag Great Lakes LLC
Michele L. Glendenning
and
Vaishali J. Patel
Price:
$117.00
View
MaxPax, LLC
Michele L. Glendenning
and
Ana Paula P. Sandee
Price:
$117.00
View
Akorn, Inc.
Michele L. Glendenning
,
Sandra A. Hughes
, and
Michele Perry-Williams
Price:
$117.00
View
Upcoming Events
13
Jul
FDA Ad and Promo Enforcement Trends: Past, Present and Future
27
Jul
Applying the Lessons of the Pandemic to Your Upcoming Trial
28
Jul
EU-MDR’s Growing Pains: Are You Current with the Latest Developments?
02
Aug
Medical Device Cybersecurity: Understand the Latest Developments
03
Aug
Pharmaceutical Process Validation: Best Practices for Success
10
Aug
Gene & Cell Therapy Regulation: Comparability and Other New Developments
Featured Products
FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485
Selecting and Implementing Electronic Document Management Systems in the EU
Featured Stories
FDA Approves Foundation Medicine’s Companion Diagnostic for Genentech’s Rozlytrek
Novartis Pays $100 Million for Mallinckrodt’s Priority Review Voucher
FDA Approves Beyond Air’s LungFit PH for Newborn Pulmonary Hypertension
FDA Grants Priority Review to Roche’s Lunsumio for Follicular Lymphoma
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
